www.fdanews.com/articles/85266-medicis-pharmaceutical-corp-is-moving-higher-on-reloxin-news
MEDICIS PHARMACEUTICAL CORP. IS MOVING HIGHER ON RELOXIN NEWS
March 14, 2006
Ipsen announced after the close on Monday that it will grant Aesthetica Ltd., a wholly owned subsidiary
of Medicis Pharmaceutical Corp. (MRX | charts | news | Powerrating), rights to
develop, distribute and commercialize Ipsen's botulinum toxin product in the U.S.,
Canada and Japan for aesthetic use by physicians. The product is commonly referred
to as Reloxin in the U.S. market and Dysport outside the U.S.
TradingMarkets.com